Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Health Behaviour Change

- PMLiVE

Cerevel Therapeutics shares positive phase 3 results for tavapadon in Parkinson’s disease

The progressive neurodegenerative disease affects seven million people worldwide

- PMLiVE

Uncovering the millennial mindset – why two thirds of HCPs feel misunderstood by pharma

By Phil Streit

- PMLiVE

Roche’s ALK inhibitor Alecensa receives FDA approval to treat early-stage NSCLC

Approximately half of all patients with early lung cancer experience cancer recurrence following surgery

- PMLiVE

Ipsen announces launch of new UK headquarters in London life sciences community

The Paddington site will serve as one of the company’s three global hubs

- PMLiVE

GSK’s shingles vaccine shown to maintain high protection in long-term study

The infectious condition affects up to one in three people globally in their lifetimes

- PMLiVE

UK scientists discover two genes offering potential drug targets against skin cancer

The three major types of skin cancer are basal cell carcinoma, squamous cell carcinoma and melanoma

- PMLiVE

Behavioural science – the route to healthcare salvation?

Industry is urged to ditch the simple slogans and instead embrace the complexity, as delving more deeply could improve success rates

- PMLiVE

The PM Society – giving back

Highlighting some of the initiatives, donations and work streams that the organisation has led

- PMLiVE

Effective Communication in Virtual Meetings: Stay Pithy – Impetus InSite Tips #4

Learn the value of concise communication in our fourth tip for optimizing virtual meetings. Discover how keeping interactions short and focused can drastically improve engagement and retention in today's fast-paced...

Impetus Digital

- PMLiVE

Takeda gains rights to Kumquat’s immune-oncology programme in deal worth over $1.2bn

The selected candidate can be developed as a monotherapy, combination therapy or both

- PMLiVE

Roche reveals promising phase 3 results for subcutaneous Ocrevus in progressive and relapsing MS

The chronic neurological condition affects more than 2.8 million people worldwide

- PMLiVE

Novartis presents positive long-term data for relapsing MS treatment Kesimpta

Approximately 85% of MS patients are initially diagnosed with relapsing forms of the neurological disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links